9R3O image
Deposition Date 2025-05-05
Release Date 2025-08-13
Last Version Date 2025-08-13
Entry Detail
PDB ID:
9R3O
Keywords:
Title:
Structure of liver pyruvate kinase in complex with fluorescent probe 4a
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.05 Å
R-Value Free:
0.23
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
C 1 2 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Isoform L-type of Pyruvate kinase PKLR
Gene (Uniprot):PKLR
Chain IDs:A, B, C, D, E, F, G, H
Chain Length:447
Number of Molecules:8
Biological Source:Homo sapiens
Primary Citation
Fluorescent binding assay for allosteric ligands of liver pyruvate kinase.
Eur.J.Med.Chem. 298 117989 117989 (2025)
PMID: 40749256 DOI: 10.1016/j.ejmech.2025.117989

Abstact

Environment-sensitive fluorescent probes are indispensable tools for studying biological systems and advancing drug discovery. This study reports the development of 4-sulfamoyl-7-aminobenzoxadiazole (SBD)-based fluorescent probes for the allosteric site of the liver isoform of pyruvate kinase (PKL). By integrating SBD moieties into known activator scaffolds, such as mitapivat and diarylsulfonamide (DASA) ligands, probes for indicator displacement assays were designed to quantify ligand interactions in the allosteric site. Compound 4a displayed dose-dependent fluorescence enhancement in response to PKL binding and was used in a competitive binding assay with unlabelled ligands: mitapivat, TEPP-46, DASA-58 and reported activator 21. Structure-activity relationship (SAR) analysis revealed key structural features influencing activity and fluorescence sensitivity. The probes report selectively on the allosteric site ligands as the binding was not affected by natural ligands, such as ADP, fructose-1,6-bisphosphate (FBP), phosphoenolpyruvate (PEP), and phenylalanine. These findings provide a practical framework for detecting allosteric ligand engagement in PKL and expand the repertoire of molecular tools for advancing PKL-targeted therapies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures